PIK3CA and neoplasm: PI3K/AKT/mTOR pathway hyperactivation has similarly been validated in TNBC cell lines and xenografts, where selective PI3K inhibitors restored antigen presentation and enhanced ICI efficacy, underscoring a tumor intrinsic driver amenable to targeted therapy [139].